cs.LGNov 15, 2026

Reasoning in the loop: antibody lead optimization by probing mechanism and measurement

Authors: Samuel Stanton, Aaron Solomon, Emily Delaney, Melanie Montgomery, Crystal Humphries, Timothy Acker, Ryan Henrici, Charbel Eid, 

Organizations: Anthropic · BigHat Biosciences

Abstract

Lab-in-the-loop systems, in which a model proposes molecules, automated assays measure their properties and the results retrain the model, are a popular approach to antibody lead optimization. These systems optimize for a specification defined with metrics computed from instrument signals, so their success depends on how well those metrics serve as proxies for the properties a drug candidate needs. When a metric is a poor proxy, neither a better model nor more data will fix it, and identifying the problem usually requires expert review. We report two campaigns run on BigHat Biosciences' Milliner platform, one on an anti-albumin nanobody (VHH) and one on an anti-mesothelin single-chain variable fragment (scFv), in which a research team and a general-purpose AI agent, Claude, brought scientific reasoning into the loop. Over seven rounds and about 1,010 design variants we built libraries from antibody lineage, structure and biophysics, and found from the raw curves that on each scaffold one thermal metric did not measure what its name implied. The libraries were built as controlled comparisons, so the results also show what each mutation contributes to each property. We fit a physical model of the curves, used it to choose metrics suited to each scaffold, and changed the experimental protocol, varying protein concentration and heating rate, to test the model against pre-registered predictions. Both leads improve on their parents in affinity, thermal stability and aggregation while improving or maintaining yield and purity.

Explore similar work

Oct 17, 2026

Aptamers as a sandbox for lab-in-the-loop agentic molecular discovery

Despite breakthroughs in AI-driven molecular generation, existing discovery pipelines operate largely in silico, with wet-lab feedback reserved for validation rather than iterative improvement. Whether large language model (LLM)-based reasoning agents can accelerate de novo discovery by iterating with lab data remains unproven. Here we use protein-binding aptamer design as a sandbox (1-2 week cycles, $1-$3 per candidate) to demonstrate a wet lab in a closed loop with AI systems. We tasked agentic pipelines with developing aptamer binders against αα-thrombin and myoglobin across three design-test-improve cycles (∼\sim1,000 candidates per round; ∼\sim4,400 constructs). Statistically significant, bead-corrected on-target hit rates among new candidates rose across rounds from 0.0% in Round 1 to 26.0% in Round 2 and 42.1% in Round 3 on αα-thrombin (37.1% excluding literature motif descendants), and from 10.2% in Round 1 to 3.7% in Round 2 and 33.5% in Round 3 on myoglobin. Single-clone bead-binding titrations of eight full-length αα-thrombin candidates confirmed concordance with pooled sequencing enrichment (Pearson r=0.90r = 0.90). In these assays, literature-derived motifs engineered by the agents to reduce off-target reactivity in the pooled screen reached apparent affinities of KD=24.6K_D = 24.6--133133 nM, whereas de novo scaffolds showed low-micromolar binding (KD>1 μK_D > 1\ μM). We also report how our pipelines used myoglobin binding data to exploit the G-quadruplex binder space, diagnose cross-reactivity as on-target specificity dropped from 75.0% to 19.1%, and recover by developing strategies that restored specificity to 72.4%. We demonstrate that empirical lab data is more valuable than existing computational proxies, showing how iterative experimental feedback enables AI agents to diagnose assay artifacts and refine molecular designs across rounds.
Oct 31, 2026

Can agents reliably design therapeutic antibodies?

Recent work has demonstrated agents driving protein design workflows, either through orchestration of specialized tools or direct manipulation of sequences. Yet the fidelity with which agents follow protein design instructions and the factors contributing to their effectiveness remain understudied. We examine agentic antibody design under two settings: when explicit molecular-editing instructions are provided and when agents receive only previously-scored sequences and are prompted to propose improvements. We call the first task-guided and the second black-box design. For the task-guided setting, we curate ten expert-validated affinity-improvement tasks and show that LLM judges closely reproduce programmatic evaluations of instruction following. We then study two augmentations: access to antibody-relevant tools and to previously scored design history. Tools improve instruction following (IF) and sequence space exploration while reducing optimization performance, whereas design history reduces IF but improves optimization performance at the expense of exploration. Finally, we combine taskguided and black-box design within an in silico optimization loop and show that our agentic optimizer performs comparably to an established Bayesian optimization baseline.
May 23, 2025

A Comprehensive Benchmark of Computational Models for Antibody--Antigen Binding Affinity

Computational antibody design requires benchmarks that measure functional binding rather than similarity to natural sequences. Here we present AbBiBench, which treats the antibody--antigen complex as the evaluation unit and harmonizes 216,560 experimental measurements spanning 13 antibodies and 9 antigens. We compare 20 computational approaches without task-specific training or fine-tuning. The analyses show that global structure-conditioned inverse folding yields the strongest and most consistent affinity rankings, whereas antibody-specific fine-tuning does not consistently improve performance. Across models, rankings are more useful for prioritizing likely affinity gains than for excluding weak variants. In a subsequent case study, multi-objective evaluation of model-generated F045-092 CDR-H3 variants for H1N1 binding revealed a trade-off between predicted binding potential and evolutionary sequence plausibility; all 21 selected candidates produced H1-reactive ELISA signals. AbBiBench provides an open framework for developing and evaluating function-aware antibody design methods.